President Donald Trump Just Fast-Tracked the Rescheduling of Marijuana, and Pot Stocks Plunged -- Here's the Nefarious Reason Why

On Dec. 18 President Trump signed an executive order to fast-track an FDA review to reclassify cannabis from Schedule I to Schedule III, following a 2023 HHS recommendation. The announcement triggered steep moves intraday — Trulieve -24%, Curaleaf -32%, Cresco Labs -39%, Green Thumb -17%, Canopy Growth -12% — because the EO explicitly forecloses federal recreational legalization through his term while enabling medical legitimacy. Rescheduling would materially improve sector fundamentals by allowing banks to provide services and by removing cannabis companies from Section 280E’s limited deductions (raising net margins and lowering effective tax rates), but it constrains the larger recreational addressable market (MJBiz 2028 high-case U.S. retail sales $56.9B, $42.8B recreational vs $14.1B medical).

Analysis

Market structure: Rescheduling to Schedule III materially re-rates business economics for medically-focused MSOs (Trulieve TCNNF, Curaleaf CURLF, Cresco CRLBF, Green Thumb GTBIF) by unlocking banking, lowering cost of capital and removing 280E — I estimate potential operating margin upside of ~8–15 percentage points over 6–18 months if IRS/DOJ follow. Losers are pure recreational plays and Canadian LPs (Canopy CGC) that counted on federal rec legalization for US expansion; TAM for federally permissible sales collapses from ~$57B to roughly the $14B medical addressable figure cited for 2028, capping long-term revenue growth.

Risk assessment: Tail risks include FDA rejecting rescheduling, DOJ/DEA delays, or IRS guidance that preserves 280E effects (low prob but high impact). Short-term (days–weeks) expect elevated volatility and funding dislocations; medium term (3–12 months) the key drivers are bank policy changes and IRS/DEA rulemaking; long term (1–3 years) industry structure will shift toward vertically integrated medical suppliers and pharmaceutical entrants. Hidden dependencies: bank risk limits, state-by-state variance in medical formularies, and compliance costs under FDA surveillance could offset margin gains.

Trade implications: Direct long on medical-leaning MSOs with capital efficiency (e.g., TRULIEVE TCNNF, CURALEAF CURLF) sized 1–3% positions, with 6–12 month horizons to capture margin re-rate; short selective Canadian LPs (CGC) or rec-centric operators that lose US optionality. Options: buy 9–12 month LEAPS calls on CURLF/CRLBF (delta ~0.35–0.45) and finance by selling 1–2 month OTM call spreads to harvest volatility. Rotate 2–4% from consumer/discretionary into healthcare/biotech names working on CBD therapeutics and banks likely to expand SME lending to MSOs.

Contrarian angles: The market likely overreacted intraday — 20–40% selloffs price in near-total collapse of all upside; however, execution risk means gains will be realized unevenly. Consensus underestimates timing friction: tangible EBITDA lift will phase in over 2–4 quarters, not instantly; conversely, unintended consequences include stricter FDA controls and pharma competition that could compress pricing long term. Historical parallel: partial regulatory reforms (e.g., Medicaid drug listings) often produce front-loaded PE multiple expansion followed by mean reversion once competitive entrants arrive.

Key Decisions for Investors

• Establish a 2–3% net long position in Curaleaf (CURLF) and/or Trulieve (TCNNF) combined, size each 1–1.5%, on weakness; target 30–50% upside within 6–12 months if FDA/DEA reschedule and IRS issues 280E relief; set stop-loss at -20% from entry.
• Open a 6–12 month call-spread on Cresco Labs (CRLBF): buy 12-month LEAPS call (delta ~0.35–0.45) and sell a 6–9 month nearer-OTM call to fund 40–60% of premium; allocate 0.5–1% of portfolio to capture margin re-rate while selling short-term vol.
• Initiate a small (1%) short or underweight position in Canopy Growth (CGC) and other Canadian LPs with material U.S. US-entry thesis; cover if federal recreational legalization re-enters legislative or executive calendar (threshold: public bill with >60% congressional support or DOJ/White House signals reversal).
• Redeploy 2–4% from general consumer discretionary into selected regional banks and payments processors that announce MSO lending/relationship pilots within 90 days (monitor bank press releases and OCC guidance); expect credit spread compression of 50–150bps for banks that onboard MSOs meaningfully.